• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

司美格鲁肽在2型糖尿病管理中的概况：设计、研发及治疗地位

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.

作者信息

Gomez-Peralta Fernando, Abreu Cristina

机构信息

Endocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain,

出版信息

Drug Des Devel Ther. 2019 Feb 20;13:731-738. doi: 10.2147/DDDT.S165372. eCollection 2019.

DOI:10.2147/DDDT.S165372
PMID:30863012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6388990/
Abstract

Type 2 diabetes mellitus (T2DM) has become one of the leading causes of morbidity and mortality in developed countries. Low efficacy, weight gain, and hypoglycemia are the main pitfalls of previous treatments for T2DM. New therapies have been designed with the aim of improving the results in efficacy and quality of life. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RA) increase glucose-dependent insulin secretion, decrease gastric emptying, and reduce postprandial glucagon secretion. The last GLP-1 RA approved by the US Food and Drug Administration and European Medicines Agency was semaglutide. This review describes its pharmacology, core clinical data coming from the randomized controlled trials included in the development program, proven cardiovascular benefits, safety issues, and precautions for the use of semaglutide in special populations. Additionally, an overview of the positioning of semaglutide in T2DM therapy and practical issues regarding semaglutide initiation are offered.

摘要

2型糖尿病（T2DM）已成为发达国家发病和死亡的主要原因之一。疗效不佳、体重增加和低血糖是既往T2DM治疗的主要缺陷。已设计出新的疗法，旨在提高疗效和生活质量。胰高血糖素样肽1（GLP-1）受体激动剂（GLP-1 RA）可增加葡萄糖依赖性胰岛素分泌，减少胃排空，并降低餐后胰高血糖素分泌。美国食品药品监督管理局和欧洲药品管理局批准的最新GLP-1 RA是司美格鲁肽。本综述描述了其药理学、来自开发项目中纳入的随机对照试验的核心临床数据、已证实的心血管益处、安全性问题以及司美格鲁肽在特殊人群中使用的注意事项。此外，还概述了司美格鲁肽在T2DM治疗中的定位以及司美格鲁肽起始治疗的实际问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/1643d696e0e0/dddt-13-731Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/8451b41f6f64/dddt-13-731Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/63f81ed58830/dddt-13-731Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/adf18e61ce56/dddt-13-731Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/1643d696e0e0/dddt-13-731Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/8451b41f6f64/dddt-13-731Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/63f81ed58830/dddt-13-731Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/adf18e61ce56/dddt-13-731Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aaf/6388990/1643d696e0e0/dddt-13-731Fig4.jpg

相似文献

1
Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.司美格鲁肽在2型糖尿病管理中的概况：设计、研发及治疗地位
Drug Des Devel Ther. 2019 Feb 20;13:731-738. doi: 10.2147/DDDT.S165372. eCollection 2019.
2
Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?司美格鲁肽用于2型糖尿病——它是最佳的胰高血糖素样肽1受体激动剂（GLP-1R激动剂）吗？
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):371-377. doi: 10.1080/17425255.2018.1441286. Epub 2018 Feb 23.
3
Semaglutide once-weekly: improved efficacy with a new safety warning.司美格鲁肽每周一次：疗效改善，新增安全性警告。
Expert Rev Clin Pharmacol. 2018 Nov;11(11):1061-1072. doi: 10.1080/17512433.2018.1534201. Epub 2018 Oct 16.
4
The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date.用于治疗2型糖尿病的口服胰高血糖素样肽-1受体激动剂的研发：迄今的证据
Drug Des Devel Ther. 2019 Aug 22;13:2985-2996. doi: 10.2147/DDDT.S166765. eCollection 2019.
5
Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.口服司美格鲁肽治疗 2 型糖尿病患者的疗效和安全性临床评价：考虑接受注射用 GLP-1 受体激动剂治疗或正在接受胰岛素治疗的患者。
Postgrad Med. 2020 Nov;132(sup2):26-36. doi: 10.1080/00325481.2020.1798127. Epub 2020 Sep 8.
6
Practical guidance for use of oral semaglutide in primary care: a narrative review.在基层医疗中使用口服司美格鲁肽的实用指南：一篇叙述性综述。
Postgrad Med. 2020 Nov;132(8):687-696. doi: 10.1080/00325481.2020.1788340. Epub 2020 Jul 9.
7
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.在治疗 2 型糖尿病方面，每周一次皮下注射司美格鲁肽的疗效、安全性和心血管结局比较：来自 SUSTAIN 1-7 试验的结果。
Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4.
8
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.口服司美格鲁肽治疗 2 型糖尿病的药理学和临床概述。
Drugs. 2021 Jun;81(9):1003-1030. doi: 10.1007/s40265-021-01499-w. Epub 2021 May 8.
9
Cardiovascular safety and benefits of GLP-1 receptor agonists.胰高血糖素样肽-1受体激动剂的心血管安全性及益处
Expert Opin Drug Saf. 2017 Mar;16(3):351-363. doi: 10.1080/14740338.2017.1281246. Epub 2017 Jan 19.
10
Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.皮下注射司美格鲁肽（NN9535）治疗 2 型糖尿病。
Expert Opin Biol Ther. 2018 Mar;18(3):343-351. doi: 10.1080/14712598.2018.1439014. Epub 2018 Feb 15.

引用本文的文献

1
Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1.帕金森病的肠脑通讯：GLP-1 对肠内分泌的调节。
Curr Neurol Neurosci Rep. 2022 Jul;22(7):335-342. doi: 10.1007/s11910-022-01196-5. Epub 2022 May 28.
2
Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.糖尿病：阿尔茨海默病的风险因素和转化治疗意义。
Eur J Neurosci. 2022 Nov;56(9):5727-5757. doi: 10.1111/ejn.15619. Epub 2022 Feb 23.
3
Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.

本文引用的文献

1
Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update.西班牙糖尿病学会（SED）关于2型糖尿病高血糖药物治疗的建议：2018年更新版
Endocrinol Diabetes Nutr (Engl Ed). 2018 Dec;65(10):611-624. doi: 10.1016/j.endinu.2018.08.004. Epub 2018 Oct 23.
2
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2018 年美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）共识报告：2 型糖尿病患者高血糖管理。
Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4.
3
司美格鲁肽，一种胰高血糖素样肽-1 受体激动剂，具有心血管获益，可用于 2 型糖尿病的治疗。
Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7.
4
Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review).糖尿病肥胖症治疗的未来展望：司美格鲁肽，一种胰高血糖素样肽1受体激动剂（综述）
Exp Ther Med. 2021 Oct;22(4):1167. doi: 10.3892/etm.2021.10601. Epub 2021 Aug 12.
5
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.皮下注射和口服司美格鲁肽制剂的临床应用观点。
Front Endocrinol (Lausanne). 2021 Jun 29;12:645507. doi: 10.3389/fendo.2021.645507. eCollection 2021.
6
A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.利拉鲁肽在“糖尿病肥胖症”现代治疗中的应用2021年更新：一篇叙述性综述
Medicina (Kaunas). 2021 Jun 29;57(7):669. doi: 10.3390/medicina57070669.
7
A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss.欧洲食品和饲料快速预警系统的系统评价：非法减肥食品补充剂的趋势
Front Pharmacol. 2021 Jan 26;11:611361. doi: 10.3389/fphar.2020.611361. eCollection 2020.
8
Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation.利拉鲁肽通过下调晚期糖基化终产物受体改善糖尿病小鼠的认知功能。
Aging (Albany NY). 2020 Nov 26;13(1):525-536. doi: 10.18632/aging.202162.
9
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.胰高血糖素样肽-1：聚焦神经退行性疾病
Front Neurosci. 2019 Oct 18;13:1112. doi: 10.3389/fnins.2019.01112. eCollection 2019.
Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study.
肥胖与主要非传染性疾病导致的无疾病年限损失：一项多队列研究。
Lancet Public Health. 2018 Oct;3(10):e490-e497. doi: 10.1016/S2468-2667(18)30139-7. Epub 2018 Sep 1.
4
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.司美格鲁肽联合基础胰岛素治疗 2 型糖尿病（SUSTAIN 5）：一项随机对照试验。
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2291-2301. doi: 10.1210/jc.2018-00070.
5
Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.司美格鲁肽作为治疗老年 2 型糖尿病患者的一种选择：SUSTAIN 1-5 试验的汇总分析。
Diabetes Obes Metab. 2018 Sep;20(9):2291-2297. doi: 10.1111/dom.13331. Epub 2018 Jun 7.
6
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.司美格鲁肽对比度拉鲁肽每周 1 次治疗 2 型糖尿病患者（SUSTAIN 7）：一项随机、开放标签、3b 期临床试验。
Lancet Diabetes Endocrinol. 2018 Apr;6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X. Epub 2018 Feb 1.
7
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.每周一次司美格鲁肽对比艾塞那肽 ER 治疗 2 型糖尿病患者的疗效和安全性（SUSTAIN 3）：一项 56 周、开放标签、随机临床试验。
Diabetes Care. 2018 Feb;41(2):258-266. doi: 10.2337/dc17-0417. Epub 2017 Dec 15.
8
8. Pharmacologic Approaches to Glycemic Treatment: .8. 血糖治疗的药物治疗方法： 。
Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85. doi: 10.2337/dc18-S008.
9
2. Classification and Diagnosis of Diabetes: .2. 糖尿病的分类和诊断： 。
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. doi: 10.2337/dc18-S002.
10
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.在肝功能损害人群中司美格鲁肽的药代动力学和耐受性。
Diabetes Obes Metab. 2018 Apr;20(4):998-1005. doi: 10.1111/dom.13186. Epub 2018 Jan 17.